MAZE THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
MAZE THERAPEUTICS, INC. (MAZE) reported Increase (Decrease) in Accounts Payable of $418.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.79M, a 241.59% decline year-over-year.
- MAZE THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.21M, a 282.04% increase year-over-year.
- MAZE THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$1.13M, a 237.03% decline year-over-year.
- MAZE THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$748.00K.
- MAZE THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$27.00K.
- MAZE THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$204.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $418.00K 10-Q · filed 2026-08-11 | -$707.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.46M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.21M 10-Q · filed 2026-05-12 | $1.09M derived: sum of 2 quarters · filed 2026-05-12 | $339.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$1.87M derived: sum of 2 quarters · filed 2026-03-25 | -$606.00K derived: sum of 3 quarters · filed 2026-08-11 | -$27.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | -$748.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $519.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.10M 10-Q · filed 2025-11-06 | $1.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.85M 10-Q · filed 2026-08-11 | $2.67M derived: sum of 3 quarters · filed 2026-08-11 | $1.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $579.00K 10-Q · filed 2026-05-12 | $1.40M derived: sum of 2 quarters · filed 2026-05-12 | $231.00K derived: sum of 3 quarters · filed 2026-05-12 | $618.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $821.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$348.00K derived: sum of 2 quarters · filed 2026-03-25 | $39.00K derived: sum of 3 quarters · filed 2026-03-25 | -$204.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | -$1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$782.00K derived: sum of 2 quarters · filed 2025-11-06 | -$1.02M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $144.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$243.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |